ApoE Peptides Suppress Microglial Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological conditions and inflammation lack effective methods to suppress microglial activation and CNS inflammation, which are key contributors to various neurological diseases and injuries.
Innovation Solution
Development of isolated peptides, such as VSRKR, VSKRR, VSRRR, VARKL, RHKKL, RHKRR, and VARRL, which mimic the receptor-binding domain of ApoE to bind to microglial receptors, suppress glial activation, and reduce inflammation, thereby treating neurological conditions and injuries.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ApoE or its receptor-binding domain is used to suppress microglial activation and CNS inflammation, then anti-inflammatory efficacy is improved, but molecular weight and complexity increase
Solution Approach 1:
The ApoE protein (299 amino acids, 34 kDa) is segmented into its functional receptor-binding domain (residues 130-150, 20 amino acids), which contains the four-α-helix motif responsible for binding to microglial receptors. This segmentation isolates the essential therapeutic function from the rest of the protein structure, creating a smaller, more manageable peptide while preserving anti-inflammatory efficacy.
Solution Approach 2:
The invention extracts only the critical receptor-binding domain (residues 130-150) from the full ApoE protein. This extracted peptide fragment (ApoE130-150) maintains the ability to bind microglial receptors and suppress glial activation, while eliminating unnecessary portions of the protein that contribute to molecular complexity without adding therapeutic value.
2Reliability
If the full ApoE protein is administered to treat neurological conditions, then therapeutic effect is improved, but pharmacokinetic properties and blood-brain barrier penetration deteriorate
Solution Approach 1:
The full ApoE protein is divided into a smaller functional unit (the 20-amino acid receptor-binding domain). This segmented peptide has improved pharmacokinetic properties including better solubility, enhanced stability, and superior ability to cross the blood-brain barrier, while retaining the core therapeutic effect of suppressing microglial activation and reducing CNS inflammation.
Solution Approach 2:
The essential therapeutic component (receptor-binding domain residues 130-150) is extracted from the full ApoE protein. This extracted peptide fragment achieves better pharmacokinetic performance and blood-brain barrier penetration compared to the complete protein, while maintaining the ability to produce the desired therapeutic effect in neurological conditions.
3Reliability
If larger protein molecules like ApoE are used, then receptor-binding capacity is improved, but blood-brain barrier penetration and delivery to CNS deteriorate
Solution Approach 1:
The ApoE protein is segmented to identify and isolate the specific region (residues 130-150) that contains the receptor-binding function. This 20-amino acid segment is sufficient to maintain binding capacity to microglial receptors while reducing molecular size from 34 kDa to a much smaller fragment, thereby improving blood-brain barrier penetration and CNS delivery.
Solution Approach 2:
The receptor-binding domain is extracted as a standalone peptide fragment from the full ApoE protein. This extracted segment preserves the essential receptor-interaction capability while eliminating the bulk of the protein mass, enabling effective delivery across the blood-brain barrier to reach CNS targets.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These peptides effectively reduce microglial activation, inflammation, and improve neurological outcomes in animal models of traumatic brain injury, intracerebral hemorrhage, and other neurological conditions by enhancing vestibulomotor and neurocognitive functions, demonstrating potential as a novel therapeutic strategy for neurological disorders.
Implementation Method 1
Peptides derived from the receptor-binding region of apoE have been demonstrated to maintain the functional activity of the intact protein
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications